the aid library

LIST OPTIONS

Filter

4226

Strategic Framework for Enhancing Prevention and Control of mpox, 2024-2027

World Health Organization WHO (2024) C_WHO

Mpox continues to affect people around the world. A new framework released today by WHO will guide health authorities, communities and other stakeholders in preventing and controlling mpox outbreaks, eliminating human-to-human transmission of the disease, and reducing spillover of the virus from ani... more

Silicosis - occupational lung disease

Mediclinic Southern Africa Mediclinic Southern Africa (2024) CC2

The Mediclinic article on silicosis provides an overview of this occupational lung disease caused by inhaling silica dust. It explains that inhaled silica particles lead to lung scarring and nodule formation, progressively impairing breathing. The article outlines symptoms such as shortness of breat... more

Silicosis - Silicosis is an occupational lung disease caused by inhaling silica dust

Mediclinic Southern Africa Mediclinic Southern Africa (2024) CC2

The Mediclinic Infohub article on silicosis provides an overview of this occupational lung disease caused by inhaling silica dust. It explains that inhaled silica particles lead to lung scarring and nodule formation, progressively impairing breathing. The article outlines symptoms such as shortness ... more

Download (233)

View PDF (519)

COLERA: INFORMAÇA O PARA PROMOTORES DE SAUDE ou ACTIVISTAS

World Health Organisation (WHO) (2019) C2

The PDF "COLERA: Informação para Promotores de Saúde" provides essential guidance for health promoters and activists on cholera. It explains that cholera is characterized by severe watery diarrhea, often resembling rice water, and sometimes vomiting. If not treated promptly, it can lead to death ... more

Download (285)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (174)

View PDF (164)

Schistosomiasis and soil-transmitted helminthiases: progress report, 2022

World Health Organization WHO (2023) C_WHO

Human schistosomiasis is caused mainly by 3 schistosome species: Schistosoma haematobium, S. mansoni and S. japonicum. S. guineensis, S. intercalatum and S. mekongi have a highly localized distribution in Central Africa and along the Mekong River in South-East Asia, respectively. Soil-transmitted h... more

Download (952)

View PDF (2166)

Kenya national palliative care guidelines
recommended

Republic of Kenya, Ministry of Health (2013) C1

Download (156)

View PDF (164)

Standard treatment guidelines oncology India

Ministry of Health & Family Welfare, India (2020) C1

Accessed Febr. 6, 2020

Download (1013)

View PDF (1144)

Linee guida dell’OMS sul trattamento farmacologico del dolore persistente nei bambini con patologie croniche gravi

World Health Organization Fondazione IRCCS, Istituto Nazionale dei Tumori (2014) C_WHO

Download (243)

View PDF (362)

EPIDEMIOLOGY OF MUSCULOSKELETAL DISORDERS IN PRIMARY SCHOOL CHILDREN IN BOSNIA AND HERZEGOVINA

Selma Azabagic, Razija Spahic, Nurka Pranjic, and Maida Mulic materia socio-medica (2016) CC

Musculoskeletal disorders represent a significant problem of modern society which are more pronounced in young people and school children. Etiology of these disorders is found in inadequate ergonomic conditions, too heavy school bag, school furniture inadequate to age, poor posture, sedentary lifest... more

Standard treatment guidelines major trauma

Ministry of Health & Family Welfare, India (2014) C1

Download (240)

View PDF (406)

Prevent Blindness through primary eye care

Programme for the Prevention of Blindness and Deafness (World Health Organisation), International Eye Foundation & CBM (2005) C_WHO

Mudança do clima e terra

International Panel on Climate Change IPCC (2019) C2

Relatório especial do IPCC sobre mudança do clima, desertificação, degradação da terra, manejo sustentável da terra, segurança alimentar, e fluxos de gases de efeito estufa em ecossistemas terrestres